Shots:

• The P-IIIb study results involve assessing of Inzess (290 mcg- qd) vs PBO in 614 adult patients on multiple abdominal symptoms with IBS-C
• The P-III study results met its 1EPs & 2EPs demonstrating overall improvement in abdominal symptoms of bloating- pain and discomfort in adults- decrease in weekly abdominal score 29.7% vs 18.3%; clinically meaningful response (40.5% vs 23.4%); diarrhea (4.6% vs 1.6%)
• Linaclotide is a guanylate cyclase-C (GC-C) agonist binds to GC-C receptor locally- approved in the US for IBS-C or chronic idiopathic constipation (CIC) and is marketed in EU for moderate to severe IBS-C with brand name Constella

Ref: Ironwood | Image: Occam Global